Browse News
Filter News
Found 63 articles
-
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
1/23/2023
BiondVax Pharmaceuticals Ltd. today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.
-
Antibody Production Market Size up to 2030 - Quantitative Research by QYResearch Medical
11/17/2022
The global antibody production market size is expected to reach USD 37.81 Billion in 2030 and register a revenue CAGR of 14.4% during the forecast period.
-
Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care
6/18/2021
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 Nucleic acid test.
-
Health Canada grants Interim Order authorization for casirivimab and imdevimab for the treatment of mild to moderate COVID-19
6/10/2021
Hoffmann-La Roche Limited announced that Health Canada has issued an Interim Order authorization for casirivimab and imdevimab, to be administered together, for the treatment of mild to moderate coronavirus disease 2019, confirmed by direct SARS-CoV-2 viral testing, in adults and adolescents who are at high-risk for progressing to hospitalization and/or death.
-
Keeping in mind that COVID-19 has dominated the news cycle, here are the top 10 stories of 2020 in no particular order.
-
Biggest Novel Drug Approvals in 2020
1/4/2021
Here’s a look at the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years. -
New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19
12/17/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19.
-
Thankful for Biopharma Breakthroughs
11/26/2020
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year. -
Late Friday, the FDA gave the green light to Regeneron's REGN-COV2, a combination of casirivimab and imdevimab.
-
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
11/22/2020
Initial doses of REGEN-COV2 will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation program
-
COVID-19 Brief: WHO Recommends Against Remdesivir, Roche Ramps Up to Produce Antibodies Treatment...
11/20/2020
The World Health Organization (WHO) recommends against using Gilead Sciences' remdesivir as a treatment for COVID-19. -
Despite the greenlight from the U.S. Food and Drug Administration as an emergency treatment, there are some questions about how effective the treatment will actually prove to be due to labeling limitations.
-
Bamlanivimab, an intravenous treatment, should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.
-
Inexpensive Nasal Spray Prevents COVID-19 Infection in Ferrets, Shows Promise for Human Trials
11/9/2020
A multi-institutional research team has developed a nasal spray that effectively blocks absorption of the SARS-CoV-2 virus in ferrets with direct contact to infected animals. -
Regeneron Reports Third Quarter 2020 Financial and Operating Results
11/5/2020
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2020 and provided a business update.
-
Remdesivir brought in $873 million in the third quarter, the first full quarter the drug has been on the market. But the drug is facing a storm of controversy.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
-
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
-
The positive findings were shared as part of the company’s Emergency Use Authorization submission for its investigational COVID-19 therapy.
-
There is an impressive amount of technological ingenuity – mRNA, monoclonal antibodies and more traditional formats – being thrown at the development of a vaccine against COVID-19.